A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479
Age 18 +
Sex Both
Phase Phase 3
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key details about the study:
- The treatment involves a combination of different therapies, which may work together to enhance effectiveness.
- This study is unique because it looks at how these therapies can be tailored to individual patients, potentially leading to better results.
- Patients in the study will receive close monitoring and support throughout the treatment process.
- The goal is to assess how well this combination therapy works compared to standard treatments.
- Researchers are also interested in understanding the side effects and overall safety of the new treatment.
- This study includes a diverse group of participants, which may help in understanding how different patients respond to the treatment.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to compare the efficacy and safety of BMS-986393 versus standard regimens in adult participants with Relapsed or Refractory and Lanalidomide-refractory Multiple Myeloma.
The purpose of this study is to compare the efficacy and safety of BMS-986393 versus standard regimens in adult participants with Relapsed or Refractory and Lanalidomide-refractory Multiple Myeloma.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
